AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for 26S proteasome non-ATPase regulatory subunit 10

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O75832

UPID:

PSD10_HUMAN

Alternative names:

26S proteasome regulatory subunit p28; Gankyrin; p28(GANK)

Alternative UPACC:

O75832; Q5U0B2; Q8IZK9

Background:

The 26S proteasome non-ATPase regulatory subunit 10, also known as Gankyrin or p28(GANK), plays a crucial role in cellular processes. It acts as a chaperone during the assembly of the 26S proteasome, particularly the PA700/19S regulatory complex, influencing proteasome structure and function. Beyond its proteasomal duties, Gankyrin regulates EGF-induced AKT activation, RAS-induced tumorigenesis, and has a pivotal role in the negative regulation of tumor suppressors RB1 and p53/TP53.

Therapeutic significance:

Understanding the role of 26S proteasome non-ATPase regulatory subunit 10 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways and tumor suppressor regulation highlights its potential as a target in cancer therapy.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.